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Abstract
Background: S100A9 protein (myeloid-related protein MRP14, also referred to as calgranulin B) is a reliable marker
of inflammation, an important proinflammatory factor of innate immunity and acts as an additional antimicrobial
peptide in the innate immune system. Evidence indicates that S100A9 contributes to Alzheimer’s disease (AD)
pathology, although the precise mechanisms are not clear.
Methods: We were interested to study the mechanisms of S100A9 release upon Aβ1-42 stimulation, the potential
roles of extracellular S100A9 depletion in Aβ-induced cytotoxicity, and the interaction with innate immune
response in THP-1 monocytic cells that have been challenged with mostly Aβ1-42 monomers instead of oligomers.
We used protein preparation, Ca2+ influx fluorescence imaging, MTT assay, siRNA knockdown, colony forming units
(CFUs) assay and western blotting techniques to perform our study.
Results: Aβ1-42 monomers elicited a marked decrease of S100A9 release into the cell culture supernatant in a
dose-dependent manner in human THP-1 monocytes. This reduction of S100A9 release was accompanied by an
increase of intracellular Ca2+ level. Aβ1-42-mediated decrease of S100A9 release was not associated with Aβ1-42-
induced cytotoxicity as measured by MTT reduction assay. This observation was confirmed with the recombinant
S100A9, which had little effect on Aβ1-42-induced cytotoxicity. Moreover, depletion of S100A9 with siRNA did not
significantly evoke the cell toxicity. On the other hand, Aβ1-42-induced extracellular S100A9 depletion resulted in
decreased antimicrobial activity of the culture supernatant after Aβ1-42 stimulation. Immunodepletion of S100A9
with anti-S100A9 also decreased the antimicrobial peptide activity of the vehicle treated culture supernatant.
Consistently, the recombinant S100A9 clearly elicited the antimicrobial peptide activity in vitro, confirming the
observed antimicrobial activity of S100A9 in the culture supernatant.
Conclusion: Collectively, our findings suggest that the mostly monomeric form of Aβ1-42 negatively regulates the
innate immune system by down-regulating the secretion of S100A9, which is likely a main mediator of
antimicrobial activity in the conditioned media of human THP-1 monocytes.
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Background
Alzheimer’s disease (AD) is the most common and still
incurable form of dementia, which primarily affects the
population over the age of 60 years. Amyloid beta (Aβ)
deposition, neurofibrillary tangle formation and neuro-
inflammation are the major pathogenetic mechanisms
that, in concert, lead to neocortical and hippocampal at-
rophy, memory dysfunction and decline of cognition in
AD [1,2]. There are currently no curative or effective
clinical treatments for AD [3].
The innate immune response and inflammatory sig-
naling play determinant roles in brain homeostasis,
neuroprotection and repair. However, altered or exces-
sive signaling in these injury defense systems contributes
to neuroinflammation and the irreversible degeneration
of brain cells [4]. Extensive innate immune gene activa-
tion reflecting chronic innate immune activation could
accompany brain aging, increasing vulnerability to cog-
nitive decline and neurodegeneration, consistent with
the emerging idea of a critical involvement of inflam-
mation in the earliest stages of AD [5]. Thus, clinical
pharmaceutical trials aimed at modulating the immune
system in AD have largely focused on dampening down
central proinflammatory innate immunity and the ma-
nipulation of systemic immunity, and its communication
with the central nervous system (CNS) [6].
Calgranulins reflecting calcium-binding properties
and high expression in granulocytes are comprised of
three proteins: S100A8 (calgranulin A, also termed as
MRP8), S100A9 (calgranulin B, also termed as MRP14)
and S100A12 (Calgranulin C). They are predominantly
expressed by neutrophils, monocytes and activated mac-
rophages in inflamed tissue [7]. These S100 calcium-
binding proteins are important molecular mediators in
a range of diseases, including microbial infections. In
particular, S100A9 protein is a reliable marker of in-
flammation and an important proinflammatory factor of
innate immunity. Elevated plasma levels of S100A9 are
associated with inflammatory disorders such as chronic
bronchitis, cystic fibrosis and rheumatoid arthritis [8].
The extracellular roles of S100A9 in leukocyte migra-
tion and chemotaxis, leukocyte activation, oxidant
scavenging, and their relevance in inflammatory pro-
cesses are in particular implicated [7,9,10]. Recent re-
ports have also suggested that S100A9 acts as an
additional antimicrobial peptide in the innate immune
system, which provides immediate protection for the
host against microbial challenge by recognizing
the presence of microorganisms and preventing their
tissue invasion, thus limiting microbial proliferation
and inflammation [11,12].
Altered expression/function of these S100 protein
members [13] has been associated with neurological dis-
eases such as cerebral ischemia [14] and traumatic brain
injury [15]. Earlier studies demonstrated that S100 pro-
teins assemble within neuritic plaques and reactive glia,
which may serve to prolong neuroinflammation associ-
ated with the pathogenesis of AD [16,17]. Our recent
study showed that S100A9 expression was increased in
the brains of Tg2576 mice, as well as in AD brains,
which proposed its potential role in the neuroin-
flammation related to the pathogenesis of AD [18,19].
Another recent study reported that S100A9 interacts
with Aβ and induces fibrillization, further supporting its
association with AD [20]. However, a mechanistic link
between S100A9 and AD pathology, and the detailed
molecular mechanism have not been clearly shown.
We focused our research on the mechanisms of
S100A9 release upon stimulation with mostly Aβ1-42
monomers, the potential roles of extracellular S100A9
depletion in Aβ-induced cytotoxicity, and the interaction
with innate immune response in THP-1 monocytic cells
that have been challenged with Aβ1-42 monomers in-
stead of oligomers. The results of the present study show
that the mostly monomeric form of Aβ1-42 negatively
regulates the innate immune system by down-regulating
the release of S100A9, which is likely a main mediator




Synthetic siRNA for S100A9 and the non-specific con-
trol pool were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Lipofectamine 2000 was
purchased from Invitrogen (Carlsbad, CA, USA). Anti-
S100A9 was acquired from R&D Systems (Minneapolis,
MN, USA). Horseradish peroxidase-conjugated anti-
mouse IgG and anti-rabbit IgG were obtained from
Jackson ImmunoResearch (West Grove, PA, USA). Acti-
nomycin, inhibitor of de novo mRNA expression, and
cycloheximide, inhibitor of protein synthesis, were
obtained from Calbiochem (La Jolla, CA, USA). The 3
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) was obtained from United States Biochemical
(Cleveland, OH, USA). The Ca2+ ionophore, ionomycin,
and an endoplasmic reticulum Ca2+ pump inhibitor,
thapsigargin, were acquired from Sigma-Aldrich
(St Louis, MO, USA). Anti-β-actin antibody and other
chemicals, including 1,2-bis(o-aminophenoxy)ethane-N,
N,N',N'-tetraacetic acid (BAPTA) and ethylene glycol
tetraacetic acid (EGTA), were also acquired from Sigma-
Aldrich.
Preparation of Aβ peptides
Aβ1-42 peptide was purchased from American Peptide
Company (Sunnyvale, CA, USA) and prepared before
use as previously described [21]. Aβ1-42 peptide was
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dissolved at 5 mM in dimethyl sulfoxide and diluted at
250 μM in double-distilled water before experiments.
This preparation contains the mostly monomeric form
of Aβ1-42 and very small amounts of dimers with larger
oligomers up to 6-mers [21].
Preparation of recombinant S100A9 protein
Human recombinant (r) S100A9 was obtained from
Dr Tessier at Laval University Hospital Center (Sainte-
Foy, Québec, Canada), expressed in Escherichia coli and
purified by previously defined protocols [22]. The purity
of protein was verified by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Specificity of
S100A9-mediated effect was controlled by THP-1 cell
treatment with heat-inactivated rS100A9 (rS100A9hi) pre-
pared by incubation at 85°C for 2 hours.
Cell culture
The human monocytic cell line THP-1 was obtained
from ATCC (Rockville, MD, USA) and maintained in
RPMI-1640 containing 10% heat-inactivated fetal calf
serum as previously described [21]. THP-1, a mono-
nuclear cell line of human origin, has been widely used
as a model of human monocytes/macrophages or micro-
glia not only because of its functional and morphological
similarities, including its capacity to activate signal
transduction pathways, but also because of functional
differences in the metabolism of rodent and human
microglial cells as previously described [23].
Experimental treatment
After being washed, THP-1 cells were incubated with
serum-free RPMI-1640 supplemented with 0.5% glucose
for 1 hour at 37°C before stimulation. The cells were
then stimulated by the addition of the mostly mono-
meric form of Aβ1-42 peptide for 24 hours in the pres-
ence or absence of rS100A9 or rS100A9hi. In some
experiments, cells were incubated with ionomycin or
thapsigargin to determine the effect of increase of intra-
cellular Ca2+ level. To deplete extracellular or intracellu-
lar Ca2+, cells were pretreated for 1 hour with ethylene
glycol tetraacetic acid (EGTA) or BAPTA, and further
incubated for 24 hours in the presence or absence of
Aβ1-42 monomers. All concentrations were selected on
the basis of the maximal effects of the drugs on their
specified targets. Vehicles were treated identically, but
did not contain Aβ1-42 or pharmacological agents as de-
scribed above. Vehicle alone exerted no detectable ef-
fects on cell viability. After stimulation with Aβ1-42
and/or the specific agents for 24 hours, total cell lysate
and the supernatant were prepared and stored at −20°C
until use for quantification of S100A9 release by western
blot analysis. The supernatant was also analyzed in par-
allel for antimicrobial activities.
MTT assay
The viability of cells was analyzed by the MTT assay to
assess mitochondrial dehydrogenase activity as previ-
ously described [24]. Only viable cells are able to reduce
MTT into a formazan product by mitochondrial de-
hydrogenase. After 24 hours of treatment of THP-1 cells
with Aβ1-42 and/or rS100A9, MTT was added to the
medium (1 mg/ml) and incubated for 4 hours at 37°C.
The medium was removed and the cells were diluted in
120 μl of 1 N HCl:isopropyl alcohol (1:24) and incubated
for 30 minutes at room temperature with shaking. The
relative formazan concentration of each supernatant was
measured by determination of the absorbance at 570 nm
in a microplate reader.
Calcium imaging and fluorescence measurements
To visualize intracellular steady-state Ca2+ levels, THP-1
cells were stained by adding Fluo 3A in its ace-
toxymethyl ester form (Fluo-3 AM) to 5 μg/ml culture
media throughout Aβ1-42 or vehicle treatment as previ-
ously described [18]. Ca2+ influx fluorescence images
were captured after treatment as indicated. Images were
recorded using an Axiovert 200 inverted microscope and
analyzed with the KS 300 analysis program (Zeiss,
Oberkochen, Germany). An increase in intracellular Ca2+
level in the different cultures was expressed as fold of the
response of the vehicle treated controls for each individual
experiment.
siRNA studies
Synthetic siRNA for S100A9 and the non-specific con-
trol pool were purchased from Santa Cruz Biotechnol-
ogy, and transfection of the RNA oligonucleotide was
performed using Lipofectamine 2000. THP-1 cells were
treated with Lipofectamine 2000 (mock transfection),
siRNA or non-specific RNA pool at the concentrations
indicated. After 24 hours of transfection, the cell viability
was measured by the MTT method.
E coli culture and treatment
E coli strain LE392 was used throughout this study.
Colonies from agar were transferred by sterile loop to
growth media and incubated aerobically in Luria Broth
(Conda, Madrid, Spain) for 2 hours at 37°C, to generate
mid-logarithmic growth cultures for use as inoculates
in experiments. Bacteria inoculum cell densities were
normalized to 5 × 105 cells/ml immediately before use.
After stimulation with Aβ1-42, the supernatant col-
lected was mixed with E coli in the ratio of 1:1.
rS100A9 and rS100A9hi were directly diluted into
serum-free RPMI-1640 and also mixed with E coli. All
stocks were incubated for 2 hours at 37°C. In some
experiments, rS100A9 was preincubated with anti-
S100A9 antibodies for 2 hours at 37°C before use.
Lee et al. Journal of Neuroinflammation 2013, 10:68 Page 3 of 11
http://www.jneuroinflammation.com/content/10/1/68
Experiments included control serial dilutions of medium
or buffer vehicle alone.
Colony forming unit (CFU) assay
Serial dilutions of incubants were prepared and streaked
onto the surface of Luria broth agar (Miller’s LB agar).
The agar plates were then incubated overnight at 37°C
and CFUs counted as previously described [25].
Preparation of human peripheral blood mononuclear cells
(PBMC)
Human PBMC were isolated from peripheral blood of
healthy subjects as previously described [24] and used
as a positive control for S100A9 in western blot analysis.
Preparations contained approximately 10% monocytes,
90% lymphocytes and <1.5% granulocytes.
Electrophoresis and western blotting
Immunoblotting was conducted as previously described
[24,26]. Equal quantities of sample proteins were separated
on the basis of molecular weight by 10% SDS-PAGE
and transferred to polyvinylidene difluoride membranes
(Millipore, Bedford, MA, USA), which were subsequently
blocked for 0.5 hours with 3% milk in Tris-buffered saline
with Tween 20. The membranes were then probed with
primary antibody diluted with 1% milk and incubated over-
night at 4°C. Signals were acquired with an enhanced
chemiluminescence system after incubation with horserad-
ish peroxidase-conjugated secondary antibodies (Jackson
ImmunoResearch). Densitometric values were normalized
versus β-actin.
Statistical analyses
Differences between groups were evaluated for statistical
significance using one-way analysis of variance (ANOVA)
with a Student’s t-test. Null hypotheses of no difference
were rejected if P values were less than 0.05.
Results
Aβ1-42 reduced extracellular release of S100A9 in human
THP-1 monocytes
To clarify the pathological mechanism related to S100A9
in AD, we measured the extracellular release of S100A9 in
response to stimulation with Aβ1-42 in human THP-1
monocytes. We used Aβ1-42 monomers instead of oligo-
mers. The treatment of THP-1 cells with Aβ1-42 mono-
mers significantly reduced the release of S100A9 at 24
hours in the conditioned media of THP-1 cells. This Aβ1-
42-mediated decrease of S100A9 secretion occurred in
a dose-dependent manner and maximal reduction of
S100A9 secretion was found to occur at a concentration
of 10 μM Aβ1-42 (Figure 1A, B). Notably, S100A9 se-
cretion was consistently reduced when de novo mRNA
expression and protein synthesis were inhibited by
actinomycin D and cycloheximide, respectively. Thus,
our data confirmed that Aβ1-42 elicited a marked de-
crease of the extracellular S100A9 release in a dose-
dependent manner in human THP-1 monocytes, and
that reduction of S100A9 release is dependent on both
transcriptional and translational activities (Figure 2A,B).
Intracellular Ca2+ level is involved in Aβ1-42-induced
depletion of extracellular S100A9
The increase of [Ca2+]i may initiate the inflammatory re-
sponse in activated microglia [27]. We observed that 10
μM Aβ oligomers extensively increased the level of [Ca2+]i
in murine microglial BV2 cells as evaluated using the
Fluo-3 AM method [18]. Thus, we investigated the role of
intracellular Ca2+ levels in Aβ1-42-mediated reduction of
S100A9 release and found that intracellular Ca2+ level is
involved in human monocytic cells. We also observed that
10 μM Aβ1-42 monomers significantly increased intracel-
lular Ca2+ levels in THP-1 cells as measured by Fluo-3
AM (Figure 3A,B). Furthermore, treatment of THP-1 cells
with the Ca2+ ionophore, ionomycin, which induces [Ca2+]i
Figure 1 S100A9 release in response to Aβ1-42 monomers in
human monocytic THP-1 cells. To measure the extracellular
release of S100A9 in response to mostly monomeric Aβ1-42
stimulation, THP-1 cells were incubated with either vehicle only (−)
or increasing amounts of Aβ1-42 for 24 hours in serum-free RPMI-
1640 medium supplemented with glucose (0.5%). (A) The cell-free
conditioned media were examined for S100A9 via protein
immunoblot. Positive control for S100A9 was shown in human
PBMC whole cell lysate. Aβ1-42 decreased S100A9 release in
conditioned media in a dose-dependent manner. Results are
representative of three independent experiments. (B) Densitometric
quantification of analyses of (A), showing the levels of S100A9
release. All data are presented as the means ± SEM (n = 3).
**P <0.01, versus vehicle treated samples. PBMC, peripheral blood
mononuclear cells.
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elevating intracellular Ca2+ concentration, induced the
Aβ1-42-evoked response decreasing the release of S100A9
(Figure 4A,D). Moreover, thapsigargin, an endoplasmic
reticulum Ca2+ pump inhibitor, which induces an increase
of intracellular Ca2+ level, also mimicked the Aβ1-42
-evoked effects. Concomitantly, the intracellular levels of
S100A9 were increased in THP-1 cells treated with either
ionomycin or thapsigargin as observed in Aβ1-42 treated
cells (Figure 4B,E). However, the Aβ1-42-evoked response
was significantly attenuated by either depletion of extracel-
lular Ca2+ with EGTA or chelation of intracellular Ca2+ by
BAPTA (Figure 4C,F). Together, these findings suggest that
extracellular depletion of S100A9 in response to Aβ1-42
monomers is dependent on an increase of intracellular
Ca2+ and S100A9 levels in human THP-1 monocytes.
Aβ1-42-induced depletion of extracellular S100A9 was
not associated with Aβ1-42-dependent cytotoxicity
To further describe the pathological mechanism related
to S100A9 in AD, the role of extracellular S100A9 deple-
tion related to the Aβ1-42-induced cytotoxicity was in-
vestigated. As shown in Figure 5, Aβ1-42 treatment
significantly increased cytotoxicity as measured by MTT
reduction assay. Addition of rS100A9 protein into the
cell culture supernatant did not significantly attenuate
the Aβ1-42-induced cytotoxicity (Figure 5A). Treatment
with rS100A9 alone in the absence of Aβ1-42 at concen-
trations up to 10 μg/ml had little effect on the cell viabil-
ity and, as expected, a similar effect was observed with
rS100A9hi (Figure 5B). In addition, depletion of S100A9
with siRNA did not significantly evoke cell toxicity
(Figure 5C). These results demonstrate that extracellular
depletion of S100A9 was not directly associated with the
Figure 2 S100A9 release process was dependent on
transcription and translation processes in human monocytic
THP-1 cells. THP-1 cells were incubated with Aβ1-42 (10 μM),
actinomycin (ActD, 100 nM) or cycloheximide (CHX, 1 μM) for 24
hours. (A) Western blot analyses were conducted to determine the
effects of actinomycin or cycloheximide on S100A9 release in the
conditioned media, as described in Figure 1. S100A9 secretion was
reduced when de novo mRNA expression and protein synthesis were
inhibited. Representative gels from three experiments are shown.
(B) Quantitative analysis of (A), showing the levels of S100A9 release.
All data are presented as the means ± SEM (n = 3). **P <0.01, versus
vehicle treated samples. ActD, actinomycin; CHX, cycloheximide.
Figure 3 Aβ1-42 monomers increased [Ca2+]i in human
monocytic THP-1 cells. (A) [Ca2+]i images obtained by Fluo-3 AM
at 24 hours after treatment with either vehicle only (−) or 10 μM
Aβ1-42 monomers (Aβ) in THP-1 cells. Scale bars represent 50 μm.
(B) The histogram showing the ratio of [Ca2+]i levels to vehicle
treated group. All data are presented as the means ± SEM (n = 3).
**P <0.01, versus vehicle treated samples. Aβ, amyloid beta.
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cytotoxicity in response to mostly Aβ1-42 monomers in
human monocytic THP-1 cells.
Aβ1-42-induced extracellular S100A9 depletion resulted
in decreased antimicrobial activity
Recent reports suggested that S100A9 acts as an additional
antimicrobial peptide in the innate immune system, which
provides immediate protection for the host against micro-
bial challenge by recognizing the presence of microorgan-
isms and preventing their tissue invasion, thus limiting
microbial proliferation and inflammation [11,12]. We fur-
ther investigated the antimicrobial activity of S100A9,
which was released into the cell culture supernatants of
THP-1 monocytes. The antimicrobial activities against
E coli were assessed with the cell culture supernatants from
vehicle or Aβ-42 treated THP-1 cells. Vehicle treated super-
natant, which contained a significant amount of S100A9,
demonstrated antimicrobial activity against E coli. However,
microbial growth was not decreased by the supernatant
from Aβ1-42 treated THP-1 cells in which the S100A9 level
was significantly reduced (Figure 6A). Moreover, rS100A9
protein clearly elicited the antimicrobial peptide activity
in vitro (Figure 6B), whereas rS100A9hi had little activity.
Consistently, immunodepletion of S100A9 with anti-
S100A9 antibodies blocked antimicrobial activity of the ve-
hicle treated supernatant (Figure 6C), confirming that the
antimicrobial activity in the vehicle treated supernatant is
S100A9-specific.
Figure 4 The decreased extracellular S1009A in response to Aβ1-42 monomers is dependent on increase of intracellular Ca2+ level in
human THP-1 monocytes. THP-1 cells were incubated with Aβ1-42 (10 μM), actinomycin (ActD, 100 nM) or cycloheximide (CHX, 1 μM) for 24
hours. Western blot analyses were conducted to determine the effects of actinomycin or cycloheximide on S100A9 release in the conditioned
media, as described in Figure 1. Ionomycin and thapsigargin mimicked the Aβ1-42-evoked response. THP-1 cells were incubated with Aβ1-42
(10 μM), ionomycin (2 μM) or thapsigargin (2 μM) for 24 hours. (A) The conditioned media and (B) total cell lysate were examined for S100A9 by
western blot analyses. (C) THP-1 cells were pretreated with EGTA (0.5 mM) or BAPTA (10 μM) for 1 hour followed by incubation with either the
vehicle only (−) or Aβ1-42 (10 μM) for 24 hours. Western blot analyses were conducted to determine the role of intracellular Ca2+ levels in
Aβ1-42-mediated reduction of S100A9 release. Ionomycin and thapsigargin, which elevate intracellular Ca2+ level, mimicked the Aβ1-42-evoked
response, decreasing S100A9 secretion. In contrast, the Aβ1-42-mediated decrease of S100A9 secretion was attenuated by either depletion of
extracellular Ca2+ with EGTA or chelation of intracellular Ca2+ by BAPTA. Representative gels from three experiments are shown. (D, E, F)
Quantitative analysis of (A, B, C) showing the levels of S100A9 release. All data are presented as the means ± SEM (n = 3). **P <0.01, versus
vehicle treated samples; ##P<0.01, versus Aβ1-42 treated samples. ActD, actinomycin; BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic
acid; CHX, cycloheximide; EGTA, ethylene glycol tetraacetic acid.
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Discussion
The present study has four main findings concerning a
mechanistic link between S100A9 and AD pathology. First,
the mostly monomeric form of Aβ1-42 markedly de-
creased S100A9 release into the cell culture supernatant of
human THP-1 monocytes in parallel with increased intra-
cellular S100A9. Second, this reduction of S100A9 release
was accompanied by increased intracellular Ca2+ level.
Third, depletion of extracellular S100A9 in response to
Aβ1-42 monomers was not associated with Aβ1-42-
induced cytotoxicity. Finally, Aβ1-42-induced extracellular
S100A9 depletion decreased antimicrobial activity of the
culture supernatant from human monocytes, which was
pathogenically challenged with Aβ1-42. Our findings sug-
gest that mostly Aβ1-42 monomers negatively regulates
the innate immune system by down-regulating the
Figure 5 Extracellular S100A9 depletion by Aβ1-42 monomers was not associated with Aβ1-42-induced cytotoxicity. (A) To investigate
the role of extracellular S100A9 depletion related to the Aβ1-42-induced cytotoxicity, THP-1 cells were incubated for 24 hours with Aβ1-42
(10 μM) in the presence of 10 μg/ml recombinant S100A9 (rS100A9) or heat inactivated rS100A9 (rS100A9hi). (B) THP-1 cells were also incubated with
increasing amounts of rS100A9 alone as indicated for 24 hours. (C) THP-1 cells were transfected with S100A9 siRNA (100 ng/ml) or control siRNA (100
ng/ml) for 24 hours. The cell viability was measured by MTT reduction activity. rS100A9 protein did not attenuate the Aβ1-42-induced cytotoxicity.
rS100A9 alone in the absence of Aβ1-42 also had little effect on the cell viability. Extracellular depletion of S100A9 with siRNA did not induce the
cytotoxicity. Values are expressed as the means ± SEM of triplicate experiments. MTT, 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Figure 6 Aβ1-42-induced extracellular S100A9 depletion resulted in decreased antimicrobial peptide activity. The antimicrobial activities
against E coli were assessed with the supernatants from vehicle or Aβ-42 treated THP-1 cells. (A) E coli were cultured with serum-free RPMI-1640
media alone or the conditioned media from THP-1 cells treated with the vehicle or Aβ1-42 (10 μM) for 24 hours. (B) To measure the antimicrobial
activities of rS100A9 protein, E coli was cultured with rS100A9 or hi-rS100A9 (each 10 μg/ml). (C) To inactivate antimicrobial activity of S100A9,
which was released into the supernatants, the conditioned media from THP-1 cells treated with the vehicle for 24 hours were pretreated with
anti-S100A9 antibodies or heat inactivated anti-S100A9 antibodies for 2 hours at 37°C. E coli were then cultured with serum-free RPMI-1640 media
alone or the conditioned media treated with anti-S100A9 antibodies or heat inactivated anti-S100A9 antibodies (anti-S100A9hi) as indicated. Data
showed that vehicle treated supernatant, which contained a significant amount of S100A9, demonstrated antimicrobial activity against E coli.
Moreover, rS100A9 protein clearly elicited the antimicrobial peptide activity in vitro. Immunodepletion of S100A9 blocked antimicrobial activity of
the vehicle treated supernatant. All data are presented as the means ± SEM (n = 3). **P <0.01, versus vehicle treated samples. CM, conditioned media.
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secretion of S100A9, which is likely a main mediator of
the antimicrobial activity in the culture supernatants of
human THP-1 monocytes.
S100A8, S100A9 and S100A12, as endogenous pro-
teins associated with inflammation, are proposed to act
as damage-associated molecular pattern (DAMP) initia-
tors of innate immunity [28]. They are found at high
concentrations in inflamed tissue, where neutrophils and
monocytes are the most abundant cell types, and are re-
leased following neutrophil necrosis [29]. S100A8/S100A9
secretion may occur during interaction of phagocytes with
endothelial cells and/or stimulation by lipopolysaccharide;
IL-1β and TNF can promote S100A8/S100A9 release from
monocytes [30,31]. Secretion may involve an energy-
dependent process requiring protein kinase C activation in
combination with a second calcium-dependent signal and
interactions with microtubules [31,32]. Consistent with
previous results that activated murine macrophages and
human monocytes secreted significant amounts of
S100A8 [33,34], this study has shown that human THP-1
monocytes secreted significant amounts of S100A9, which
might be involved in autocrine/paracrine activities under-
lining the inflammatory process; although underlying mo-
lecular mechanisms of S100A9 secretion in human THP-1
monocytes remains to be determined.
S100A9 was increased within neuritic plaques and
reactive glia, and was proposed to participate in the
neuroinflammation associated with the pathogenesis of
AD [17]. A recent study also reported that S100A9 inter-
acts with Aβ1-40 and induces its fibrillization, further
supporting its association with AD [20]. Consistent with
previous observations, our recent study has shown that
S100A9 expression was increased in the brains of
Tg2576 mice and AD patients [18]. The toxic oligomeric
forms of Aβ increased intracellular S100A9 levels in
parallel with increases of [Ca2+]i and up-regulated
S100A9 was found to be involved in the production of
proinflammatory cytokines in BV2 cells [18]. Together,
these findings propose the potential role of excessive
S100A9 expression elicited by Aβ oligomers in the
neuroinflammation related to the learning and memory
impairment in AD patients, and suggest S100A9 as a
possible target for the pathogenesis of AD [18,19]. On
the other hand, it is noteworthy that the present study
has shown for the first time, to our knowledge, that the
mostly monomeric form of Aβ1-42 led to a marked de-
crease of S100A9 secretion, accompanied by a mild
increase of intracellular Ca2+ level in human THP-1
monocytes. Furthermore, since S100A9 has Ca2+ binding
capacity, this extracellular depletion of S100A9 in re-
sponse to Aβ1-42 monomers appears to be a conse-
quence of increased intracellular S100A9 in parallel with
the increased [Ca2+]i. A recent study has demonstrated a
link between extracellular Ca2+ entry and a formation of
Ca2+-dependent heterocomplexes of S100A9, which is
a probable prerequisite for its intracellular biological
activities such as nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH oxidase) activation in
myeloid cells [35]. This association of increased Ca2+
level with increased intracellular heterotetramers of
S100A9 strongly supports our study.
The oligomeric forms of Aβ exhibit stronger cytotox-
icity than the monomeric form or the less toxic insoluble
fibrillary form through their ability to bind lipid bilayers
and cause uncontrolled influx of extracellular Ca2+, with
devastating consequences for cellular Ca2+ homeostasis
[36-38]. The present study, in which mostly Aβ1-42
monomers instead of oligomers were used, has demon-
strated that Aβ1-42 monomers as measured by MTT
assay exhibited cell toxicity in human THP-1 cells. Im-
portantly, depletion of extracellular S100A9 release by
Aβ1-42 monomers or siRNA was found to have little ef-
fect on the cell viability of human monocytic cells.
Moreover, the recombinant S100A9 did not significantly
evoke cell toxicity and had little effect on Aβ1-42-induced
cytotoxicity in human THP-1 monocytes.
While some aspects of excessive S100A9 could drive
disease progression through the inflammation-induced
up-regulation of proinflammatory cytokines, as shown in
our previous study [18], there is also evidence that
S100A9 may exert neuroprotective action. According to
published reports, the proinflammatory functions of
S100A9 tended to underplay important regulatory, anti-
oxidant and protective properties [9,10]. S100A9 in-
teraction with Aβ1-40 resulted in reduced S100A9
cytotoxicity by the binding of S100A9 toxic species to
Aβ1-40 amyloid structures [20]. Consequently, it was
implied that secreted S100A9 during inflammation pro-
moted the formation of amyloid plaques and that plaque
formation may be the result of a protective response
within the brain of AD patients, in part mediated by
S100A9 [20]. Taken together, these findings suggest
that S100A9 could mediate proinflammatory and anti-
inflammatory effects, depending on the monomeric or
oligomeric forms of Aβ species [39], the precise protocol
used, including the excess or depleted concentrations, dur-
ation of exposure, overall immune environment, different
cell types and species studied, and disease states; although
the reason why S100A9 apparently mediated different ef-
fects on cell toxicity is not yet understood. Further studies
are needed to clarify the apparent controversy, and to de-
termine both intracellular and extracellular S100A9 using
the toxic oligomeric form of Aβ1-42.
Antimicrobial peptides may serve as a line of defense,
and defensins are a family of antimicrobial peptides [40].
A previous report suggested that S100A9 (MRP14) is an
additional antimicrobial peptide that forms calprotectin
(MRP8/14) heterodimer with S100A8 (MRP8) [41].
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Consequently, acting as an antimicrobial peptide in the
innate immune system, S100A9 could provide immedi-
ate protection for the host against microbial challenge
by recognizing the presence of microorganisms and
preventing their tissue invasion, thus limiting microbial
proliferation and inflammation. It is noteworthy that
S100A9 is released more from damaged cells and may
play a major antimicrobial role [42]. Importantly, our
results have shown that Aβ1-42-induced extracellular
S100A9 depletion resulted in decreased antimicrobial
activity of the culture supernatant of human THP-1
monocytes. This observation was confirmed by im-
munodepletion of S100A9 with anti-S100A9, which
decreased the antimicrobial activity of the culture
supernatant of the vehicle treated cells. Furthermore,
the recombinant S100A9 elicited the antimicrobial pep-
tide activity in vitro.
This is the first report to demonstrate that the mostly
monomeric soluble form of Aβ1-42 negatively regulates
the innate immune system by down-regulating the se-
cretion of S100A9, which subsequently reduces the
S100A9-dependent antimicrobial peptide activity in the
culture supernatants of human THP-1 monocytes. This
finding stands in stark contrast to recent reports dem-
onstrating that Aβ1-42 possess antimicrobial activity to
kill bacteria under the appropriate conditions, which
favor the formation of oligomers of Aβ peptide [25,43].
Further research will be required to demonstrate
whether the oligomeric form of Aβ1-42 would act to-
gether or in parallel with S100A9 to exert its antimicro-
bial property, and how different forms of Aβ species
such as the toxic oligomeric form of Aβ1-42 versus the
less toxic monomeric form of Aβ1-42 dysregulate or
play a host defense role in vivo.
A large body of data supports a central role for
neuroinflammation in AD neuropathology and Aβ as
the source of AD-associated inflammation [4,6]. Given
that inflammatory response in the immunologically
privileged CNS is mediated by the innate immune sys-
tem, our data raise the possibility that rather than Aβ
acting as a sole independent initiator of neuro-
inflammation, increased Aβ may trigger dysregulation
of the innate immune system through depletion of
extracellular S100A9 release from monocytes and de-
crease of its antimicrobial activity to protect against in-
vading microbes. Increased microbial infection may
further trigger a self-perpetuating innate immune re-
sponse leading to an inappropriate inflammatory re-
sponse in the CNS and subsequent production of Aβ,
although the underlying cause of the aberrant neuro-
inflammation in AD patients still remains unclear. A
number of studies reporting infection of the CNS of AD
patients with various microbial pathogens [44-48]
strongly support our study.
Conclusion
Collectively, our data indicate that Aβ1-42 monomers
decrease the secretion of S100A9 in situations where
Aβ1-42 enhances cytotoxicity. Furthermore, our findings
suggest that the mostly monomeric form of Aβ1-42
negatively regulates the innate immune system by down-
regulating the extracellular release of S100A9, which
possesses antimicrobial peptide activity in human mono-
cytes. The results of this study, at least in part, support
the notion that increased amounts of Aβ1-42 are not
only toxic to human monocyte but also disrupt its nor-
mal physiological role for a host defense in the innate
immune system, thereby contributing to an increased
microbial infection in AD patients. Consequently, the re-
sults of this study have important implications for on-
going and future AD treatment strategies. However, the
relevance of these findings in vivo remains to be clearly
elucidated.
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